Memo Therapeutics raises €33.3M Series B round
16 February 2022· Zurich, Switzerland· biotech, drug_discovery, antibody_therapeutics, b2b, deep_science
The proceeds will be used to advance clinical development of its best- and first-in-class neutralizing antibody, MTX-005, targeting BK virus infection in renal transplant patients through Phase 2 clinical development. In addition, Memo Therapeutics AG will use the funding to develop and expand its antibody pipeline and secure new partnering agreements.
Investors
LeadSwisscanto Invest
Also participating
Zürcher KantonalbankVerve VenturesVesalius BiocapitalAdjuvant CapitalGF GroupFresenius Medical Care Ventures
About Memo Therapeutics
Stage
Series C
Headquarters
Zurich, Switzerland
Founded
2012
Team Size
21–50
Sectors
biotechdrug_discoveryantibody_therapeuticsb2bdeep_science